Antibody Optimization & Engineering Services

To improve clinical suitability, antibody lead candidates often require optimization, including humanization, affinity maturation and/or liability de-risking. AVS Bio's expert antibody engineering team has a track record of success in the humanization of antibodies from species such as mouse, rabbit, camelids and chicken, and the team is highly experienced with affinity maturation and de-risking molecular optimization.

Resource:

• Service Sheet Antibody Development

Multiparametric Humanization

AVS Bio humanizes animal-derived antibodies in under two months, reducing risk and accelerating therapeutic development. Our proprietary high throughput 'CDR grafting' technology, which advances the targeted mutagenesis strategy for both framework and CDR residues to enable humanness optimization and early de-risking, accelerates data-driven lead selection. Using a symbiotic approach, our in silico humanization workflow is integrated with in silico developability profiling to simultaneously humanize and de-risk your lead antibodies, generating a well characterized, diverse panel of humanized and de-risked lead variants per lead candidate.

Affinity maturation

Affinity is a critical property of therapeutic antibodies, and lead candidates with functional characteristics of interest may require affinity finetuning or improvement for optimal efficacy. At AVS Bio, our experienced antibody engineering team can apply different affinity maturation strategies to increase antibody affinity.

Phage display-based

We boost antibody performance with phage display, screening up to 10⁹ CDR variants. When structural models are available, we target key binding residues for even greater precision — delivering faster, more effective affinity maturation.

Single amino acid and combinatorial mutant panel screening

AVS Bio refines affinity maturation by generating large panels of single amino acid CDR mutants. Each residue is replaced with nine representative amino acids and tested for binding strength. Top performers are then combined into multi-mutants to identify candidates with optimal affinity.

Epitope-guided variant design

AVS Bio advances the affinity maturation process using high-throughput experimental epitope mapping data generated by our partner. Based on identified key interacting residues, AVS Bio's antibody engineering team generates an in silico-based antibody-antigen docking model that serves as the basis for the design of optimized clones. This set of around 20 clones will be lab tested for affinity.

Liability De-Risking

Liability de-risking addresses chemical and physical vulnerabilities in an antibody sequence — such as deamidation sites, oxidation-prone residues, and aggregation-prone regions — that can compromise stability, efficacy, or safety in development. AVS Bio's engineering team identifies sequence liabilities flagged in developability profiling and generates improved variants that retain binding function while removing developability risks.

Bispecific Design

Bispecific antibodies engage two distinct targets simultaneously, enabling novel mechanisms of action in oncology (T-cell engagement, dual checkpoint blockade) and immunology. AVS Bio supports bispecific antibody design and reformatting, applying our characterization and production capabilities to evaluate and advance these more complex molecules.

Frequently Asked Questions

Q: What is antibody humanization and why is it important?

A: Antibody humanization is the process of modifying a non-human antibody (typically murine) to more closely resemble a human antibody sequence, reducing the risk of immune rejection when used therapeutically. AVS Bio uses computational tools and structure-based design approaches to humanize antibodies while preserving target binding affinity. Humanization is a standard step for any non-human antibody intended for human therapeutic use.

Q: What is affinity maturation for antibodies?

A: Affinity maturation is the process of improving an antibody's binding affinity for its target antigen through iterative or specific mutagenesis and selection. It mimics the natural process by which B cells refine antibody binding during an immune response. AVS Bio uses computational modeling and in vitro selection methods to achieve affinity improvements while maintaining or improving other developability properties.

Q: What makes an antibody suitable for therapeutic development?

A: A therapeutic antibody must demonstrate high target specificity, appropriate binding affinity (typically in the 1–10 nM range), low immunogenicity in humans, favorable pharmacokinetics, and manufacturing scalability. AVS Bio's developability profiling and optimization services directly address these criteria, with humanization, affinity maturation, and stability engineering available to advance lead candidates toward clinical suitability.